Paclitaxel and pegylated liposomal doxorubicin in recurrent head and neck cancer: Clinical and unexpected pharmacokinetic interactions

Anticancer Research

Volumn 28, Issue 4 C, 2008, Pages 2519-2527

  Airoldi, Mario ^a   Cattel, Luigi ^b   Milla, Paola ^b   Pedani, Fulvia ^a   Garzaro, Massimiliano ^a   Dosio, Franco ^b  

^a MOLINETTE HOSPITAL   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

Caelyx; Chemotherapy; Doxil; Head and neck cancer; Pharmacokinetics; Taxol

Indexed keywords

CREMOPHOR; DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; PACLITAXEL;

ADULT; AGED; ANEMIA; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; BLOOD SAMPLING; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTINUOUS INFUSION; CONTROLLED STUDY; DIARRHEA; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FEMALE; FLUID RETENTION; GRANULOCYTOPENIA; HAND FOOT SYNDROME; HEAD AND NECK CANCER; HUMAN; HYPOPHARYNX CANCER; INFECTION; LARYNX CANCER; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OROPHARYNX CANCER; PATIENT COMPLIANCE; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RANDOMIZATION; RECURRENT CANCER; SIDE EFFECT; STATISTICAL SIGNIFICANCE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; FEMALE; GLYCEROL; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PACLITAXEL; POLYETHYLENE GLYCOLS;

EID: 48849110415     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. The Liverpool Head and Neck Oncology Group: A phase III randomised trial of cisplatinum, methotrextate, cisplatinum + methotrexate and cisplatinum + 5-FU in end stage squamous carcinoma of the head and neck. Br J Cancer 61: 311-315, 1990.
2. Gibson MK, Li Y, Murphy B, Hussain MHA, DeConti RC, Ensley J and Forastiere AA: Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group. J Clin Oncol 23: 3562-3567, 2005.
3. Forastiere AA, Shank D, Neuberg D, Taylor SG 4th, DeConti RC and Adams G: Final report of a phase II evaluation of paclitaxel in patients with advanced squamous cell carcinoma of the head and neck: an Eastern Cooperative Oncology Group trial (PA390). Cancer 82: 2270-2274, 1998.
4. Catimel G, Verweij J, Mattijssen V, Hanauske A, Piccart M, Wanders J, Franklin H, Le Bail N, Clavel M and Kaye SB: Docetaxel (Taxotere): an active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. EORTC Early Clinical Trials Group. Ann Oncol 5: 533-537, 1994.
5. Catimel G, Vermorken JB, Clavel M, de Mulder P, Judson I, Sessa C, Piccart M, Bruntsch U, Verweij J, Wanders J, Franklin H and Kaye SB: A phase II study of gemcitabine (LY 188011) in patients with advanced squamous cell carcinoma of the head and neck. EORTC Early Clinical Trials Group. Ann Oncol 5: 543-547, 1994.
6. Schrijvers D and Vermerken JB: Taxanes in the treatment of head and neck cancer. Curr Opin Oncol 17: 218-224, 2005.
7. Harrington KJ, Lewanski C, Northcote AD, Whittaker J, Peters AM, Vile RG and Stewart JS: Phase II study of pegilated liposomal doxorubicin as induction chemotherapy for patients with squamous cell cancer of the head and neck. Eur J Cancer 37: 2015-2022, 2001.
8. Faivre S, Alsabe H, Djafari L, Janot F, Julieron M, Domenge C, Djazouli K, Armand JP, Luboinski B and Raymond E: Locoregional effects of pegylated liposomal doxorubicin (Caelyx) in irradiated area: a phase I-II study in patients with recurrent squamous cell carcinoma of the head and neck. Eur J Cancer 40: 1517-1521, 2004.
9. Caponigro F, Comelia P, Budillon A, Bryce J, Avallone A, De Rosa V, Ionna F and Comelia G: Phase I study of Caelyx (doxorubicin HCL, pegylated liposomal) in recurrent or metastatic head and neck cancer. Ann Oncol 11: 339-342, 2000.
10. Fountzilas G, Papakostas P, Dafni U, Makatsoris T, Karina M, Kalogera-Fountzila A, Maniadakis N, Aravantinos G, Syrigos K, Bamias A, Christodoulou C, Economopoulos T, Kalofonos H, Nikolaou A, Angouridakis N, Stathopoulos G, Bafaloukos D, Pavlidis N and Daniilidis J: Paclitaxel and gemcitabine vs. paclitaxel and pegylated liposomal doxorubicin in advanced non-nasopharyngeal head and neck cancer. An efficacy and cost analysis randomized study conducted by the Hellenic Cooperative Oncology Group. Ann Oncol 17: 1560-1567, 2006.
11. Koukourakis MI, Koukouraki S, Giatromanolaki A, Archimandritis SC, Skarlatos J, Beroukas K, Bizakis JG, Retails G, Karkavitsas N and Helidonis ES: Liposomal doxorubicin and conventionally fractionated radiotherapy in the treatment of locally advanced non-small cell lung cancer and head and neck cancer. J Clin Oncol 17: 3512-3521, 1999.
12. Rigatos SK, Tsavdaridis D, Athanasiadis A, Stathopoulos JG and Stathopoulos GP: Paclitaxel and liposomal doxorubicin (Caelyx) combination in advanced breast cancer patients: a phase II study. Oncol Rep 10: 1817-1819, 2003
13. Pérez-López ME, Curiel T, Gómez JG and Jorge M: Role of pegylated liposomal doxorubicin (Caelyx) in the treatment of relapsing ovarian cancer. Anticancer Drugs 18: 611-617, 2007.
14. Briasoulis E, Pentheroudakis G, Karavasilis V, Tzamakou E, Rammou D and Pavlidis N: Weekly paclitaxel combined with pegylated liposomal doxorubicin (Caelyx™) given every 4 weeks: dose-finding and pharmacokinetic study in patients with advanced solid tumors. Ann Oncol 15: 1566-1573, 2004.
15. Briasoulis E, Karavasilis V, Tzamakou E, Rammou D, Soulti K, Piperidou C and Pavlidis N: Interaction pharmacokinetics of pegylated liposomal doxorubicin (Caelyx) on coadministration with paclitaxel and docetaxel. Cane Chemother Pharmacol 53: 452-457, 2004.
16. Campos SM, Matulonis UA, Penson RT, Lee H, Berkowitz RS, Duska LR, Fuller AF Jr, Wilson KS, Puchalski TA, Supko JG and Seiden MV: Phase II study of liposomal doxorubicin and weekly paclitaxel for recurrent Mullerian tumors. Gynecol Oncol 90: 610-618, 2003.
17. Janinis J, Stathopoulos GP, Nikolaidis P, Kalofonos HP, Kalogera-Fountzila A, Samantas E, Aravantinos G, Anagnostopoulos A, Tolis C, Makatsoris T, Rigatos SK, Bafaloukos D, Dimopoulos MA, Daniilidis J and Fountzilas G: Pegylated liposomal doxorubicin hydrochloride (PLD) and paclitaxel in recurrent or metastatic head and neck carcinoma: a phase I/II study conducted by the Hellenic Cooperative Oncology Group (HeCOG). Anticancer Drugs 15: 479-487, 2004.
18. WHO handbook for reporting results of cancer treatment. WHO, Geneva, 1979.
19. Lee SH, Yoo SD and Lee KH: Rapid and sensitive determination of paclitaxel in mouse plasma by high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 724: 357-363, 1999.
20. Chin DL, Lum BL and Sikic BI: Rapid determination of PEGylated liposomal doxorubicin and its major metabolite in human plasma by ultraviolet-visible high-performance liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci 779: 259-269, 2002.
21. Rose LM, Tillery KF, el Dareer SM and Hill DL: High-performance liquid chromatographic determination of doxorubicin and its metabolites in plasma and tissue. J Chromatogr 425: 419-423, 1988.
22. Sparreboom A, Loos WJ, Verweij J, De Vos AI, Van der Burg MEL, Stoter G and Nooter K: Quantitation of cremophor EL in human plasma samples using a colorimetric dye-binding microassay. Anal. Biochem 255: 171-175, 1998.
23. Cattel L, Ceruti M and Dosio F: From conventional to stealth liposomes: a new frontier in cancer chemotherapy. J Chemother 16(Suppl 4): 94-97, 2004.
24. Cattel L, Passera R, Katsaros D, Medail M, Milla P and Ferrero AM: Pegylated liposomal doxorubicin and vinorelbine in recurrent ovarian carcinoma: a pharmacokinetic study on alternate administration sequences. Anticancer Res 26: 745-750, 2006.
25. Fahr A, van Hoogevest P, May S, Bergstrand N and S Leigh ML: Transfer of lipophilic drugs between liposomal membranes and biological interfaces: consequences for drug delivery. Eur J Phar Sci 26: 251-265, 2005.
26. Amer MH, Al-Sarraf M and Vaitkevicius VK: Factors that affect response to chemotherapy and survival of patients with advanced head and neck cancer. Cancer 43: 2202-2206, 1979.
27. Jacobs C, Lyman G, Velez-García E, Sridhar KS, Knight W, Hochster H, Goodnough LT, Mortimer JE, Einhorn LH and Schacter L: A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J Clin Oncol 10: 257-263, 1992.
28. Al-Sarraf M: Cisplatin combinations in the treatment of head and neck cancer. Semin Oncol 21(Suppl 12): 28-34, 1994.
29. Pivot X, Niyikiza C, Poissonnet G, Dassonville O, Bensadoun RJ, Guardiola E, Foa C, Benezery K, Demard F, Thyss A and Schneider M: Clinical prognostic factors for patients with recurrent head and neck cancer: implications for randomized trials. Oncology 61: 197-204, 2001.